Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02848274 · ClinicalTrials.gov registry record

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

A clinical trial of Non-Hodgkin's Lymphoma and Mycosis Fungoides, sponsored by Stanford University.

Recruiting
Registry status
2,000
Enrollment target
13
Study locations

NCT02848274: Recruiting study of Non-Hodgkin's Lymphoma and Mycosis Fungoides, sponsored by Stanford University.

NCT02848274 is a study of Non-Hodgkin's Lymphoma and Mycosis Fungoides that is actively recruiting participants, run by Stanford University. The registered enrollment target is 2,000 participants, above the 190-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (953% higher). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02848274, a study of Non-Hodgkin's Lymphoma and Mycosis Fungoides, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
2,000 participants
Enrollment target
13
Study locations

Study Summary

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.

Study Locations (13)

Other

  • Hospital Italiano de Buenos Aires - Buenos Aires
  • Peter MacCallum Cancer Center, - Melbourne
  • University of Sao Paulo Medical School - São Paulo
  • Peking University First Hospital - Beijing
  • The University of Tokyo - Tokyo
  • University Hospitals Birmingham - Birmingham

California

  • City of Hope - Duarte
  • Stanford University, School of Medicine - Palo Alto

Iowa

  • University of Iowa - Iowa City

New Jersey

  • Hackensack University Medical Center - Hackensack

Pennsylvania

  • University of Pittsburg - Pittsburgh

Texas

  • University of Texas Southwestern - Dallas

Utah

  • University of Utah Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2016-10
Est. Completion 2027-03
Stanford University

1,744 total trials

What NCT02848274 shows while recruiting

NCT02848274 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 190-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (953% higher).

The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 0 interventions.

NCT02848274 lists 13 locations in 7 states (Other, California, Iowa).

Frequently Asked Questions

What is clinical trial NCT02848274 about?

NCT02848274 is a clinical study titled "ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome". The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups f...

What is the current status of trial NCT02848274?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2016-10. Estimated completion is 2027-03.

What conditions does trial NCT02848274 study?

This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Mycosis Fungoides.

Who is sponsoring clinical trial NCT02848274?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02848274 being conducted?

This trial has 13 study locations across California, Iowa, New Jersey, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Hodgkin's Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02848274's enrollment target sits among peer trials

2,000 2nd of 63 higher than 61 of 63 other Non-Hodgkin's Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02848274, the US trial registry maintained by the National Library of Medicine. NCT02848274 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.